Figure 2
AMC predicts the efficacy of PD-1/PD-L1 inhibitors
(A) The difference of AMC levels in benefit (n=58) and nonbenefit (n=49) group treated with PD-1/PD-L1 inhibitors. (B) Kaplan–Meier plot for PFS of patients with AMC high and low levels treated with PD-1/PD-L1 inhibitors. (C) The difference of AMC levels in benefit (n=14) and nonbenefit (n=19) group treated with PD-1 inhibitors. (D) Kaplan–Meier plot for PFS of patients with AMC high and low levels treated with PD-1 inhibitors. (E) The difference of AMC levels in benefit (n=44) and nonbenefit (n=30) group treated with PD-L1 inhibitors. (F) Kaplan–Meier plot for PFS of patients with AMC high and low levels treated with PD-L1 inhibitors.